Last updated on August 2019

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)


Brief description of study

Study AG348-C-006 will evaluate the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase deficiency (PKD), who are not regularly receiving blood transfusions. Participants will be randomized 1:1 to receive either AG-348 or matching placebo. The study is comprised of two parts. During the Part 1 Dose Optimization Period of the study, participants will start on a dose of 5 mg AG-348 administered twice daily. Over the course of Part 1 each participant's dose will be optimized individually, up to a maximum dose of 50 milligrams (mg), twice daily. During the Part 2 Fixed-Dose Period, participants will receive AG-348 at their optimized dose from Part 1.

Clinical Study Identifier: NCT03548220

Find a site near you

Start Over

Stanford University

Palo Alto, CA United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Duke University

Durham, NC United States
  Connect »

H pital de la Timone

Marseille, Cedex 5, France
  Connect »

Yeungnam University Hospital

Daegu 705-703, Korea, Republic of
  Connect »

Yeungnam University Hospital

Gyeongsang, Korea, Republic of
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

Manchester Royal Infirmary

Manchester, United Kingdom
  Connect »

Phoenix Children's Hospital

Phoenix, AZ United States
  Connect »